HLA-C and type 1 diabetes mellitus: If β cell MHC class II presentation was a predominant feature in T1D patients, we would have expected to observe disease exacerbation with IMCY-0098 treatment, as the MHC class II epitope IMCY-0098 contains (i.e., C20-A1) is known to be naturally processed from proinsulin [43].